Joseph Maxwell

Company: Takeda Pharmaceutical

Job title: Director - Early Clinical Development, Translational Biomarker Lead, GI-TAU

Bio:

Joseph has spent the last 20 years working in drug development. An immunologist by training, he has worked in early discovery at Amgen and AbbVie identifying new drug targets and mechanisms for inflammatory diseases, particularly inflammatory bowel disease. He then worked with a diverse team at Finch Therapeutics to develop a rationally selected microbial consortium for treatment of ulcerative colitis. For the last 5 years he has been a translational biomarker lead at Takeda, involved in microbiome and rare disease programs. He is currently leading biomarker and translational efforts for Takeda’s celiac disease franchise.

Seminars:

Understanding Pathologist Variability Helps Define Endpoints & Support Digital Pathology Processes In Celiac Disease 1:30 pm

Celiac disease clinical trials are expected by regulators to show changes in histology endpoints Digital pathology makes measurement and storage of data much easier but still requires clear alignment among pathologists for how their measurements will be done Application of feedback from pathologists can support improvements in the digital pathology process for late stage clinical…Read more

day: Conference Day One